Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05676931 · ClinicalTrials.gov registry record · Phase 2
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
A Phase 2 study of Advanced Non-Small-Cell Lung Cancer, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 2
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT05676931: Active Phase 2 study of Advanced Non-Small-Cell Lung Cancer, sponsored by Gilead Sciences.
NCT05676931 is a Phase 2 study of Advanced Non-Small-Cell Lung Cancer that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 400 participants, above the 364-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05676931, a Phase 2 study of Advanced Non-Small-Cell Lung Cancer, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG Zimberelimab
- DRUG Quemliclustat
- DRUG Domvanalimab
- DRUG Platinum-Based Doublet
Study Locations (20)
Other
- CHU Bordeaux Centre Francois Magendie Hôpital du Haut Lévèque - Bordeaux
- Hospices Civils de Lyon Centre Hospitalier Lyon Sud - Lyon
- Institut De Cancerologie Strasbourg Europe ICANS - Strasboug
- Hopital FOCH - Suresnes
- LTD High Technology Hospital Medcenter - Batumi
- Caucasus Medical Center - Tbilisi
- Israel Georgian Medical Research Clinic Healthycore - Tbilisi
Florida
- Memorial Cancer Institute at Memorial Regional Hospital - Hollywood
- Hematology Oncology Associates Of The Treasure Coast - Port Saint Lucie
- Florida Cancer Specialists (Administration and Drug Shipment) - The Villages
Alabama
- University of Alabama at Birmingham (UAB) - Birmingham
California
- University of California San Diego (UCSD) - La Jolla
Illinois
- Northwestern Memorial Hospital - Chicago
Louisiana
- Ochsner Clinic Foundation - Jefferson
Michigan
- Henry Ford Hospital - Detroit
Washington
- Medical Oncology Associated, PS (dba Summit Cancer Centers) - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2027-12 |
| Phase | Phase 2 |
What the registry record for NCT05676931 still lists
NCT05676931 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, above the 364-participant average among 22 other Advanced Non-Small-Cell Lung Cancer trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Advanced Non-Small-Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Docetaxel is the first listed.
NCT05676931 names 20 study sites across 12 states, led by Other, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT05676931 about?
NCT05676931 is a clinical study titled "Study With Various Immunotherapy Treatments in Participants With Lung Cancer". The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tolerability of immunotherapy-based combination therapy.
What is the current status of trial NCT05676931?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 400 participants. The study started on 2023-02-21. Estimated completion is 2027-12.
What conditions does trial NCT05676931 study?
This clinical trial studies the following conditions: Advanced Non-Small-Cell Lung Cancer.
What interventions are being tested in trial NCT05676931?
The interventions under investigation include: Docetaxel (DRUG), Zimberelimab (DRUG), Quemliclustat (DRUG), Domvanalimab (DRUG), Platinum-Based Doublet (DRUG).
Who is sponsoring clinical trial NCT05676931?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05676931 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Non-Small-Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05676931's enrollment target sits among peer trials
400 8th of 22 higher than 15 of 22 other Advanced Non-Small-Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Non-Small-Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
RECRUITING · Phase 2
-
Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG
RECRUITING · Phase 2
-
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
ACTIVE NOT RECRUITING · Phase 2
-
A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI